抗体名: Anti-Human DLL3 Antibody (SAA0168)(流式抗体) 亚型: IgG1, kappa 浓度: 1 mg/ml % 是否单克隆: 是 靶点: DLL3 免疫原: Human 宿主: Human 用途: 仅用于科研 保质期: 1 year 应用范围: FCM 产地: France 标记物: Unconjugate 品牌: AntibodySystem 包装规格: 100ug ...
纳米抗体(nanobody,Nb), 即重链单域抗体VHH (variable domain of heavy chain of heavy-chainantibody) ,该类抗体只包含一个重链可变区(VHH)和CH2,CH3区,相比于其他抗体,轻链天然缺失。纳米抗体晶体直径2.5nm,长4nm,是自然存在的可以和抗原结合的最小片段。
Customer Reviews and Q&As There are currently no customer reviews or questions for Recombinant Human Anti-BCMA x Human Anti-CD3 Bispecific Antibody (scFv-IgG) (BSSG-H200). Click the button below to contact us or submit your feedback about this product....
CD3 & DLL3 CD3 & EGFR CD3 & EPCAM CD3 & FAP CD3 & FcRH5 CD3 & FOLR1 CD3 & GD2 CD3 & gpA33 CD3 & GPC3 CD3 & GPNMB CD3 & HBVgp3 CD3 & HER2 CD3 & HIV-1 gp120 CD3 & HIV-1 gp41 CD3 & HN CD3 & IGF1R CD3 & IL2R ...
CBP antibody; CBP_HUMAN antibody; CREB binding protein antibody; CREB-binding protein antibody; Crebbp antibody; Cyclic AMP responsive enhancer binding protein antibody; KAT3A antibody; RSTS antibody; RTS antibody; Rubinstein Taybi syndrome antibody Raised in Rabbit Species Reactivity Human,Mouse,Rat Im...
价格:￥电议 更新日期:2025/3/21 16:18:21 生产地:中国大陆 产品型号:50-9096-41 简单介绍:Anti-Human Osteopontin eFluor? 660 25 tests ebioscience Anti-Human Osteopontin eFluor? 660 25 tests 50-9096-41,ebioscience代理,ebioscience50-9096-41,ebioscience全国总代,ebioscience...
IV. Antibody binding prevents factor VIII proteolysis by thrombin. Ann Clin Lab Sci. 1986 Nov-Dec;16(6):497-501. [Article] Details2. Vitamin K-dependent protein C Kind Protein Organism Humans Pharmacological action Unknown Actions Substrate General Function Protein C is a vitamin K-dependent ...
A first-in-human,phase 1 trial of the anti-DLL4antibody (OMP-21M18)targeting cancer stem cells (CSC)in patients with advanced solid tumors. Smith DC,Eisenberg P,Stagg R,Manikhas G,Pavlovskiy A,Sikic B,et al. Clinical Cancer Research . 2014...
Purpose Navicixizumab (OMP-305B83) is a bispecific antibody that inhibits delta-like ligand 4 and vascular endothelial growth factor. This Phase 1a trial assessed escalating doses of navicixizumab in refractory solid tumors patients. Design A 3 + 3 dose escalation design was used followed...
There are currently no customer reviews or questions for Recombinant Human Anti-BCMA x Human Anti-CD3 Bispecific Antibody (Minibody) (MiniB-H200). Click the button below to contact us or submit your feedback about this product. PRODUCTS